Title: A nanobody recognizes a unique conserved epitope and potently neutralizes against the SARS-CoV-2 omicron variants.

Publication date: Jun 09, 2023

The SARS-CoV2 Omicron variant sub-lineages spread rapidly worldwide, mostly due to their immune-evasive properties. This has put a significant part of the population at risk for severe disease and underscores the need for effective anti-SARS-CoV-2 agents against emergent strains in vulnerable patients. Camelid nanobodies are attractive therapeutic candidates due to their high stability, ease of large-scale production and potential for delivery via inhalation. Here, we characterize the RBD-specific nanobody W25 and show superior neutralization activity towards Omicron sub-lineages in comparison to all other SARS-CoV2 variants. Structure analysis of W25 in complex with the SARS-CoV2 spike glycoprotein shows that W25 engages an RBD epitope not covered by any of the antibodies previously approved for emergency use. In vivo evaluation of W25 prophylactic and therapeutic treatments across multiple SARS-CoV-2 variant infection models, together with W25 biodistribution analysis in mice, demonstrates favorable pre-clinical properties. Together, these data endorse W25 for further clinical development.

Open Access PDF

Concepts Keywords
Antibodies Clinical
Camelid Cov
Nanobodies Cov2
Prophylactic Epitope
Severe Lineages


Type Source Name
disease VO population
disease VO effective
disease IDO production
disease VO Glycoprotein
disease MESH emergency
disease MESH infection
disease MESH severe acute respiratory syndrome
disease VO vaccine
disease IDO virulence
drug DRUGBANK Angiotensin II
disease MESH COVID 19
disease VO USA
disease IDO entity
disease MESH respiratory diseases
disease VO Respiratory syncytial virus
disease MESH virus infection
disease VO immunized
disease VO dose
disease MESH Infectious Diseases
drug DRUGBANK Amino acids
drug DRUGBANK Sodium lauryl sulfate
disease MESH dissociation
drug DRUGBANK Fosfomycin
disease VO inactivation
disease VO injection
disease VO organ
disease VO Viruses
disease IDO assay
drug DRUGBANK Trestolone
disease MESH weight loss
disease VO URE
disease MESH viremia
drug DRUGBANK Indium
disease IDO blood
disease VO intranasal route
drug DRUGBANK Proline
drug DRUGBANK L-Alanine
drug DRUGBANK Glycine
disease IDO infectivity
disease IDO replication
disease VO efficient
drug DRUGBANK Coenzyme M
disease VO efficiency
disease VO vaccination
disease IDO cell
drug DRUGBANK Riboprine
drug DRUGBANK Etoperidone
disease IDO facility
drug DRUGBANK Tretamine
disease MESH ARC
drug DRUGBANK 3 7 11 15-Tetramethyl-Hexadecan-1-Ol
drug DRUGBANK Ademetionine
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Carboxyamidotriazole
disease IDO host
drug DRUGBANK Guanosine
disease MESH Piedra
disease MESH respiratory syncytial virus infection
disease VO effectiveness
disease MESH lung diseases
disease MESH Hendra virus infections
disease MESH influenza
drug DRUGBANK Tricyclazole
disease VO subunit vaccine
disease VO Flavivirus
disease VO NS1
drug DRUGBANK Efavirenz
disease VO Dengue virus
drug DRUGBANK Immune Globulin Human
drug DRUGBANK Flurbiprofen
drug DRUGBANK L-Glutamine
disease VO protocol
disease VO Mycoplasma
drug DRUGBANK Tromethamine
drug DRUGBANK Tetracycline
drug DRUGBANK Nitrogen
drug DRUGBANK Ampicillin
drug DRUGBANK Dextrose unspecified form
disease VO Bacteria
drug DRUGBANK Isopropyl beta-D-thiogalactopyranoside
drug DRUGBANK Edetic Acid
drug DRUGBANK Sucrose
drug DRUGBANK Imidazole
drug DRUGBANK Myricetin
disease VO volume
drug DRUGBANK Activated charcoal
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Phosphate ion
drug DRUGBANK Esomeprazole
drug DRUGBANK Methylergometrine
drug DRUGBANK Xylazine
disease VO intraperitoneal administration
disease VO report
drug DRUGBANK Gentian violet cation
drug DRUGBANK Water
drug DRUGBANK Zoledronic acid
disease VO gene
disease VO time
drug DRUGBANK Chloride ion
drug DRUGBANK Pentetic acid
drug DRUGBANK Sodium carbonate
disease VO storage
drug DRUGBANK Sevoflurane
disease VO company
disease VO ANOVA

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *